{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:26:14Z","timestamp":1784633174220,"version":"3.55.0"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010753","name":"National Health Laboratory Service Trust Fund","doi-asserted-by":"publisher","award":["PR2223704"],"award-info":[{"award-number":["PR2223704"]}],"id":[{"id":"10.13039\/501100010753","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Pretoria School of Medicine Research Committee","award":["PR2223704"],"award-info":[{"award-number":["PR2223704"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Antiretroviral therapy (ART) has reduced the mortality and morbidity associated with HIV. However, irrespective of treatment, people living with HIV remain at a higher risk of developing non-AIDS-associated diseases. In 2019, the World Health Organization recommended the transition from efavirenz (EFV)- to dolutegravir (DTG)-based ART. Data on the impact of this transition are still limited. The current study therefore investigated the metabolic profiles, cytokine inflammatory responses, and platelet activation before and after the treatment transition. Plasma samples from nine virally suppressed adults living with HIV and sixteen healthy, HIV-uninfected individuals residing in Gauteng, South Africa were compared. Metabolite and cytokine profiles, and markers associated with platelet activation, were investigated with untargeted proton magnetic resonance metabolomics, multiplex suspension bead array immunoassays, and sandwich enzyme-linked immunosorbent assays, respectively. In those individuals with normal C-reactive protein levels, the transition to a DTG-based ART regimen resulted in decreased concentrations of acetoacetic acid, creatinine, adenosine monophosphate, 1,7-dimethylxanthine, glycolic acid, 3-hydroxybutyric acid, urea, and lysine. Moreover, increased levels of formic acid, glucose, lactic acid, myo-inositol, valine, glycolic acid, and 3-hydroxybutyric acid were observed. Notably, levels of interleukin-6, platelet-derived growth factor-BB, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor\u2013alpha, soluble cluster of differentiation 40 ligand, as well as regulated on activation, normal T-cell expressed and secreted (RANTES) reached levels close to those observed in the healthy control participants. The elevated concentration of macrophage inflammatory protein-1 alpha was the only marker indicative of elevated levels of inflammation associated with DTG-based treatment. The transition from EFV- to DTG-based regimens therefore appears to be of potential benefit with metabolic and inflammatory markers, as well as those associated with cardiovascular disease and other chronic non-AIDS-related diseases, reaching levels similar to those observed in individuals not living with HIV.<\/jats:p>","DOI":"10.3390\/v16091462","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T04:14:07Z","timestamp":1726460047000},"page":"1462","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-9155","authenticated-orcid":false,"given":"Crystal G.","family":"Roux","sequence":"first","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-5768","authenticated-orcid":false,"given":"Shayne","family":"Mason","sequence":"additional","affiliation":[{"name":"Human Metabolomics, Faculty of Natural and Agricultural Sciences, North-West University, Potchefstroom 2520, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6355-6095","authenticated-orcid":false,"given":"Louise D. V.","family":"du Toit","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-1092","authenticated-orcid":false,"given":"Jan-Gert","family":"Nel","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-922X","authenticated-orcid":false,"given":"Theresa M.","family":"Rossouw","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-4472","authenticated-orcid":false,"given":"Helen C.","family":"Steel","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/eji.200790063","article-title":"Correction: A history of AIDS: Looking back to see ahead","volume":"38","author":"Greene","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_3","unstructured":"(2024, January 21). 2024 Global AIDS Report\u2014The Urgency of Now: AIDS at a Crossroads. Available online: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf."},{"key":"ref_4","unstructured":"(2024, August 10). South Africa Country Factsheets. Available online: https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/UNAIDS_FactSheet."},{"key":"ref_5","unstructured":"(2024, March 18). Updated Recommendations on First-Line Second-Line Antiretroviral Regimens Post-Exposure Prophylaxis Recommendations on Early Infant Diagnosis of H.I.V.. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/277395\/WHO-CDS-HIV-18.51-eng.pdf?sequence=1."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: A multicentre prospective study from the RESPOND cohort consortium","volume":"9","author":"Neesgaard","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Corti, N., Menzaghi, B., Orofino, G., Guastavigna, M., Lagi, F., Di Biagio, A., Taramasso, L., De Socio, G.V., Molteni, C., and Madeddu, G. (2024). Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study. Viruses, 16.","DOI":"10.3390\/v16040613"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/COH.0000000000000445","article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: Meta-analysis of randomized trials","volume":"13","author":"Hill","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/eurheartj\/ehn573","article-title":"Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: The Framingham Heart Study","volume":"30","author":"Mahabadi","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ckj\/sfz106","article-title":"A journey from microenvironment to macroenvironment: The role of metaflammation and epigenetic changes in cardiorenal disease","volume":"12","author":"Kanbay","year":"2019","journal-title":"Clin. Kidney J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2050312120965752","DOI":"10.1177\/2050312120965752","article-title":"Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer","volume":"8","author":"Amin","year":"2020","journal-title":"SAGE Open Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, Z., Shang, H., and Jiang, Y. (2017). Chemokines and Chemokine Receptors: Accomplices for Human Immunodeficiency Virus Infection and Latency. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01274"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/1547691X.2022.2142705","article-title":"Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism","volume":"19","author":"Madzime","year":"2022","journal-title":"J. Immunotoxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11306-018-1372-6","article-title":"Miniaturized (1)H-NMR method for analyzing limited-quantity samples applied to a mouse model of Leigh disease","volume":"14","author":"Mason","year":"2018","journal-title":"Metabolomics"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Munshi, S.U., Rewari, B.B., Bhavesh, N.S., and Jameel, S. (2013). Nuclear Magnetic Resonance Based Profiling of Biofluids Reveals Metabolic Dysregulation in HIV-Infected Persons and Those on Anti-Retroviral Therapy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064298"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/jac\/dkv098","article-title":"Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines","volume":"70","author":"Funes","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00691-18","DOI":"10.1128\/AAC.00691-18","article-title":"Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line","volume":"62","author":"Li","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: What we already know and questions that need to be answered","volume":"70","author":"Apostolova","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"P120","DOI":"10.1186\/1758-2652-11-S1-P120","article-title":"Efavirenz induces alterations in lipid metabolism through AMPK activation","volume":"11","author":"Ballesteros","year":"2008","journal-title":"J. Int. AIDS Soc."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Grabacka, M., Pierzchalska, M., Dean, M., and Reiss, K. (2016). Regulation of Ketone Body Metabolism and the Role of PPAR\u03b1. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122093"},{"key":"ref_23","unstructured":"Dhillon, K.K., and Gupta, S. (2024). Biochemistry, Ketogenesis, StatPearls Publishing LLC."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"du Toit, L.D.V., Mason, S., van Reenen, M., Rossouw, T.M., and Louw, R. (2024). Metabolic Alterations in Mothers Living with HIV and Their HIV-Exposed, Uninfected Infants. Viruses, 16.","DOI":"10.3390\/v16020313"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2295435","DOI":"10.1080\/07853890.2023.2295435","article-title":"Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study","volume":"55","author":"Jemal","year":"2023","journal-title":"Ann. Med."},{"key":"ref_26","first-page":"1","article-title":"Clinical, biochemical and CT-scan characteristics of obesity onset in patients under dolutegravir in comparison with low-dose-efavirenz: A pilot study in Cameroon","volume":"22","author":"Kouanfack","year":"2021","journal-title":"Health Sci. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e25899","DOI":"10.1002\/jia2.25899","article-title":"Weight gain during the dolutegravir transition in the African Cohort Study","volume":"25","author":"Esber","year":"2022","journal-title":"J. Int. AIDS Soc."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yang, P., Liu, W., Chen, Y., and Gong, A.D. (2022). Engineering the glyoxylate cycle for chemical bioproduction. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.1066651"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/COH.0000000000000434","article-title":"The microbiome and HIV persistence: Implications for viral remission and cure","volume":"13","author":"Koay","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/COH.0000000000000234","article-title":"Microbial translocation and microbiome dysbiosis in HIV-associated immune activation","volume":"11","author":"Zevin","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_32","unstructured":"Zemaitis, M.R., Foris, L.A., Katta, S., and Bashir, K. (2024). Uremia. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_33","first-page":"237","article-title":"Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes","volume":"15","author":"Campbell","year":"1987","journal-title":"Drug Metab. Dispos."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1968450","DOI":"10.1155\/2018\/1968450","article-title":"Inositols in Insulin Signaling and Glucose Metabolism","volume":"2018","author":"Bevilacqua","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/17425247.2012.701616","article-title":"Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects","volume":"9","author":"Carlomagno","year":"2012","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3602608","DOI":"10.1155\/2020\/3602608","article-title":"Correlation between the Serum Platelet-Derived Growth Factor, Angiopoietin-1, and Severity of Coronary Heart Disease","volume":"2020","author":"Pang","year":"2020","journal-title":"Cardiol. Res. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cytogfr.2004.03.004","article-title":"PDGF and cardiovascular disease","volume":"15","author":"Raines","year":"2004","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1007\/s00520-022-07103-5","article-title":"Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)","volume":"30","author":"Link","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0151","article-title":"The colony-stimulating factors and cancer","volume":"1","author":"Metcalf","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S262566","article-title":"GM-CSF: A Promising Target in Inflammation and Autoimmunity","volume":"9","author":"Lee","year":"2020","journal-title":"Immunotargets Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/337471a0","article-title":"Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate","volume":"337","author":"Bussolino","year":"1989","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood-2011-07-367102","article-title":"Norepinephrine reuptake inhibition promotes mobilization in mice: Potential impact to rescue low stem cell yields","volume":"119","author":"Lucas","year":"2012","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jiw173","article-title":"Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer during HIV Infection","volume":"214","author":"Borges","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sindhu, S., Akhter, N., Wilson, A., Thomas, R., Arefanian, H., Al Madhoun, A., Al-Mulla, F., and Ahmad, R. (2020). MIP-1\u03b1 Expression Induced by Co-Stimulation of Human Monocytic Cells with Palmitate and TNF-\u03b1 Involves the TLR4-IRF3 Pathway and Is Amplified by Oxidative Stress. Cells, 9.","DOI":"10.3390\/cells9081799"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ijlh.12084","article-title":"Platelets: Bridging hemostasis, inflammation, and immunity","volume":"35","author":"Jenne","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pbj.2017.05.005","article-title":"Role of platelets in immune system and inflammation","volume":"2","author":"Sonmez","year":"2017","journal-title":"Porto Biomed. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Madzime, M., Rossouw, T.M., Theron, A.J., Anderson, R., and Steel, H.C. (2021). Interactions of HIV and Antiretroviral Therapy with Neutrophils and Platelets. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.634386"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mesquita, E.C., Hottz, E.D., Amancio, R.T., Carneiro, A.B., Palhinha, L., Coelho, L.E., Grinsztejn, B., Zimmerman, G.A., Rondina, M.T., and Weyrich, A.S. (2018). Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-33403-0"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1128\/JVI.00136-06","article-title":"DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets","volume":"80","author":"Chaipan","year":"2006","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Davidson, D.C., Schifitto, G., and Maggirwar, S.B. (2013). Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals. PLoS ONE., 8.","DOI":"10.1371\/journal.pone.0059950"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tcm.2015.10.004","article-title":"Metabolic syndrome update","volume":"26","author":"Grundy","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_52","first-page":"e984","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"120948","DOI":"10.1016\/j.lfs.2022.120948","article-title":"Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes","volume":"308","author":"Domingo","year":"2022","journal-title":"Life Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3892\/ijmm_00000302","article-title":"The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3-L1 adipocytes: Role of the NF-kappaB pathway","volume":"24","author":"Zoico","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/cid\/ciac949","article-title":"Weight and Metabolic Changes after Switching from Tenofovir Alafenamide\/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)\/FTC + DTG, and TDF\/FTC\/Efavirenz to TDF\/Lamivudine\/DTG","volume":"76","author":"Bosch","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): Week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12981-022-00467-y","article-title":"Prevalence and risk factors of high cholesterol and triglycerides among people with HIV in Texas","volume":"19","author":"Buendia","year":"2022","journal-title":"AIDS Res. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1462\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:56:10Z","timestamp":1760111770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["v16091462"],"URL":"https:\/\/doi.org\/10.3390\/v16091462","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]}}}